STOCK TITAN

[Form 4] Kineta, Inc. Common Stock Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Kineta Director Raymond J. Bartoszek reported multiple stock transactions on June 23-25, 2025:

  • Exercised 12,500 stock options at $0.611 per share
  • Disposed of 4,706 shares at $0.26 per share through tax withholding (F)
  • Received 6,000 new shares as a grant on June 25

Following these transactions, Bartoszek directly owns 31,000 shares and indirectly controls 1,750,474 additional shares through: RLB Holdings Connecticut LLC (1,748,473 shares), his son (1,001 shares), and daughter (1,000 shares). The stock option exercise was triggered by an Optionholder Treatment Agreement dated June 16, 2025, related to a merger agreement between Kineta and TuHURA Biosciences. The options, granted under the 2022 Equity Incentive Plan, became fully vested on June 23, 2025.

Il Direttore di Kineta, Raymond J. Bartoszek, ha riportato diverse operazioni azionarie tra il 23 e il 25 giugno 2025:

  • Ha esercitato 12.500 opzioni su azioni al prezzo di 0,611$ per azione
  • Ha ceduto 4.706 azioni a 0,26$ ciascuna tramite ritenuta fiscale (F)
  • Ha ricevuto 6.000 nuove azioni come premio il 25 giugno

Dopo queste operazioni, Bartoszek possiede direttamente 31.000 azioni e controlla indirettamente 1.750.474 azioni aggiuntive tramite: RLB Holdings Connecticut LLC (1.748.473 azioni), suo figlio (1.001 azioni) e sua figlia (1.000 azioni). L'esercizio delle opzioni è stato attivato da un Accordo di Trattamento per i Titolari di Opzioni datato 16 giugno 2025, collegato a un accordo di fusione tra Kineta e TuHURA Biosciences. Le opzioni, concesse nell'ambito del Piano di Incentivi Azionari 2022, sono diventate completamente maturate il 23 giugno 2025.

El Director de Kineta, Raymond J. Bartoszek, informó múltiples transacciones de acciones entre el 23 y 25 de junio de 2025:

  • Ejerció 12,500 opciones sobre acciones a $0.611 por acción
  • Dispuso de 4,706 acciones a $0.26 por acción mediante retención fiscal (F)
  • Recibió 6,000 nuevas acciones como concesión el 25 de junio

Tras estas transacciones, Bartoszek posee directamente 31,000 acciones y controla indirectamente 1,750,474 acciones adicionales a través de: RLB Holdings Connecticut LLC (1,748,473 acciones), su hijo (1,001 acciones) y su hija (1,000 acciones). El ejercicio de las opciones se activó mediante un Acuerdo de Tratamiento para los Tenedores de Opciones fechado el 16 de junio de 2025, relacionado con un acuerdo de fusión entre Kineta y TuHURA Biosciences. Las opciones, otorgadas bajo el Plan de Incentivos de Capital 2022, se consolidaron completamente el 23 de junio de 2025.

키네타 이사 레이몬드 J. 바르토섹은 2025년 6월 23일부터 25일까지 여러 주식 거래를 보고했습니다:

  • 주당 0.611달러에 12,500주 스톡옵션 행사
  • 세금 원천징수(F)를 통해 주당 0.26달러에 4,706주 처분
  • 6월 25일에 6,000주 신규 주식 보조금 수령

이 거래들 이후 바르토섹은 직접 31,000주를 보유하고 있으며, RLB Holdings Connecticut LLC(1,748,473주), 아들(1,001주), 딸(1,000주)을 통해 추가로 1,750,474주를 간접적으로 통제하고 있습니다. 스톡옵션 행사는 2025년 6월 16일자 옵션 보유자 처리 계약에 의해 촉발되었으며, 이는 키네타와 투후라 바이오사이언스 간의 합병 계약과 관련이 있습니다. 2022년 주식 인센티브 플랜에 따라 부여된 옵션은 2025년 6월 23일에 완전히 권리가 확정되었습니다.

Le directeur de Kineta, Raymond J. Bartoszek, a déclaré plusieurs transactions d’actions du 23 au 25 juin 2025 :

  • Exercice de 12 500 options d’achat d’actions à 0,611 $ par action
  • Disposition de 4 706 actions à 0,26 $ chacune via retenue fiscale (F)
  • Réception de 6 000 nouvelles actions en tant que subvention le 25 juin

À la suite de ces opérations, Bartoszek détient directement 31 000 actions et contrôle indirectement 1 750 474 actions supplémentaires par l’intermédiaire de : RLB Holdings Connecticut LLC (1 748 473 actions), son fils (1 001 actions) et sa fille (1 000 actions). L’exercice des options a été déclenché par un accord de traitement des détenteurs d’options daté du 16 juin 2025, lié à un accord de fusion entre Kineta et TuHURA Biosciences. Les options, attribuées dans le cadre du Plan d’incitation à l’actionnariat 2022, sont devenues entièrement acquises le 23 juin 2025.

Kineta-Direktor Raymond J. Bartoszek meldete mehrere Aktiengeschäfte vom 23. bis 25. Juni 2025:

  • Ausübung von 12.500 Aktienoptionen zu je 0,611 $
  • Veräußerung von 4.706 Aktien zu 0,26 $ pro Aktie durch Steuerabzug (F)
  • Erhalt von 6.000 neuen Aktien als Zuteilung am 25. Juni

Nach diesen Transaktionen besitzt Bartoszek direkt 31.000 Aktien und kontrolliert indirekt 1.750.474 zusätzliche Aktien über: RLB Holdings Connecticut LLC (1.748.473 Aktien), seinen Sohn (1.001 Aktien) und seine Tochter (1.000 Aktien). Die Ausübung der Optionen wurde durch eine Optionsinhaber-Behandlungsvereinbarung vom 16. Juni 2025 ausgelöst, die im Zusammenhang mit einem Fusionsvertrag zwischen Kineta und TuHURA Biosciences steht. Die unter dem Equity Incentive Plan 2022 gewährten Optionen wurden am 23. Juni 2025 vollständig unverfallbar.

Positive
  • Director received 6,000 shares as compensation grant, demonstrating continued alignment with shareholder interests
  • Director maintains significant indirect ownership of 1.75M shares through RLB Holdings Connecticut LLC, showing substantial long-term commitment to the company
Negative
  • None.

Il Direttore di Kineta, Raymond J. Bartoszek, ha riportato diverse operazioni azionarie tra il 23 e il 25 giugno 2025:

  • Ha esercitato 12.500 opzioni su azioni al prezzo di 0,611$ per azione
  • Ha ceduto 4.706 azioni a 0,26$ ciascuna tramite ritenuta fiscale (F)
  • Ha ricevuto 6.000 nuove azioni come premio il 25 giugno

Dopo queste operazioni, Bartoszek possiede direttamente 31.000 azioni e controlla indirettamente 1.750.474 azioni aggiuntive tramite: RLB Holdings Connecticut LLC (1.748.473 azioni), suo figlio (1.001 azioni) e sua figlia (1.000 azioni). L'esercizio delle opzioni è stato attivato da un Accordo di Trattamento per i Titolari di Opzioni datato 16 giugno 2025, collegato a un accordo di fusione tra Kineta e TuHURA Biosciences. Le opzioni, concesse nell'ambito del Piano di Incentivi Azionari 2022, sono diventate completamente maturate il 23 giugno 2025.

El Director de Kineta, Raymond J. Bartoszek, informó múltiples transacciones de acciones entre el 23 y 25 de junio de 2025:

  • Ejerció 12,500 opciones sobre acciones a $0.611 por acción
  • Dispuso de 4,706 acciones a $0.26 por acción mediante retención fiscal (F)
  • Recibió 6,000 nuevas acciones como concesión el 25 de junio

Tras estas transacciones, Bartoszek posee directamente 31,000 acciones y controla indirectamente 1,750,474 acciones adicionales a través de: RLB Holdings Connecticut LLC (1,748,473 acciones), su hijo (1,001 acciones) y su hija (1,000 acciones). El ejercicio de las opciones se activó mediante un Acuerdo de Tratamiento para los Tenedores de Opciones fechado el 16 de junio de 2025, relacionado con un acuerdo de fusión entre Kineta y TuHURA Biosciences. Las opciones, otorgadas bajo el Plan de Incentivos de Capital 2022, se consolidaron completamente el 23 de junio de 2025.

키네타 이사 레이몬드 J. 바르토섹은 2025년 6월 23일부터 25일까지 여러 주식 거래를 보고했습니다:

  • 주당 0.611달러에 12,500주 스톡옵션 행사
  • 세금 원천징수(F)를 통해 주당 0.26달러에 4,706주 처분
  • 6월 25일에 6,000주 신규 주식 보조금 수령

이 거래들 이후 바르토섹은 직접 31,000주를 보유하고 있으며, RLB Holdings Connecticut LLC(1,748,473주), 아들(1,001주), 딸(1,000주)을 통해 추가로 1,750,474주를 간접적으로 통제하고 있습니다. 스톡옵션 행사는 2025년 6월 16일자 옵션 보유자 처리 계약에 의해 촉발되었으며, 이는 키네타와 투후라 바이오사이언스 간의 합병 계약과 관련이 있습니다. 2022년 주식 인센티브 플랜에 따라 부여된 옵션은 2025년 6월 23일에 완전히 권리가 확정되었습니다.

Le directeur de Kineta, Raymond J. Bartoszek, a déclaré plusieurs transactions d’actions du 23 au 25 juin 2025 :

  • Exercice de 12 500 options d’achat d’actions à 0,611 $ par action
  • Disposition de 4 706 actions à 0,26 $ chacune via retenue fiscale (F)
  • Réception de 6 000 nouvelles actions en tant que subvention le 25 juin

À la suite de ces opérations, Bartoszek détient directement 31 000 actions et contrôle indirectement 1 750 474 actions supplémentaires par l’intermédiaire de : RLB Holdings Connecticut LLC (1 748 473 actions), son fils (1 001 actions) et sa fille (1 000 actions). L’exercice des options a été déclenché par un accord de traitement des détenteurs d’options daté du 16 juin 2025, lié à un accord de fusion entre Kineta et TuHURA Biosciences. Les options, attribuées dans le cadre du Plan d’incitation à l’actionnariat 2022, sont devenues entièrement acquises le 23 juin 2025.

Kineta-Direktor Raymond J. Bartoszek meldete mehrere Aktiengeschäfte vom 23. bis 25. Juni 2025:

  • Ausübung von 12.500 Aktienoptionen zu je 0,611 $
  • Veräußerung von 4.706 Aktien zu 0,26 $ pro Aktie durch Steuerabzug (F)
  • Erhalt von 6.000 neuen Aktien als Zuteilung am 25. Juni

Nach diesen Transaktionen besitzt Bartoszek direkt 31.000 Aktien und kontrolliert indirekt 1.750.474 zusätzliche Aktien über: RLB Holdings Connecticut LLC (1.748.473 Aktien), seinen Sohn (1.001 Aktien) und seine Tochter (1.000 Aktien). Die Ausübung der Optionen wurde durch eine Optionsinhaber-Behandlungsvereinbarung vom 16. Juni 2025 ausgelöst, die im Zusammenhang mit einem Fusionsvertrag zwischen Kineta und TuHURA Biosciences steht. Die unter dem Equity Incentive Plan 2022 gewährten Optionen wurden am 23. Juni 2025 vollständig unverfallbar.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bartoszek Raymond J.

(Last) (First) (Middle)
C/O KINETA, INC.
7683 SE 27TH STREET, SUITE 481

(Street)
MERCER ISLAND WA 98040

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KINETA, INC./DE [ KANT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/23/2025 M 12,500 A $0.611 29,706 D
Common Stock 06/23/2025 F 4,706 D $0.26 25,000 D
Common Stock 06/25/2025 A 6,000 A $0 31,000 D
Common Stock 1,748,473 I By RLB Holdings Connecticut, LLC(1)
Common Stock 1,001 I By son
Common Stock 1,000 I By daughter
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.611 06/23/2025 M 12,500 (2) 09/03/2034 Common Stock 12,500 $0 0 D
Explanation of Responses:
1. The Reporting Person is a managing member of RLB Holdings Connecticut, LLC ("RLB") and shares voting and dispositive power over the shares held by RLB. As such, the Reporting Person may be deemed to beneficially own such shares held by RLB.
2. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.
/s/ Nanette Agustines, as Attorney-in-Fact 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Raymond Bartoszek make in KA stock on June 23, 2025?

On June 23, 2025, Raymond Bartoszek exercised 12,500 stock options at $0.611 per share (acquired) and then disposed of 4,706 shares at $0.26 per share through a tax withholding transaction (F code). Additionally, on June 25, 2025, he acquired 6,000 shares at $0.

How many shares of KA stock does Raymond Bartoszek own directly and indirectly?

Raymond Bartoszek owns 31,000 shares directly and has indirect ownership of 1,750,474 shares, including 1,748,473 shares through RLB Holdings Connecticut, LLC, 1,001 shares through his son, and 1,000 shares through his daughter.

What was the exercise price of KA stock options that Bartoszek exercised?

Raymond Bartoszek exercised stock options with a conversion price of $0.611 per share. These options were originally set to expire on September 3, 2034, but became fully vested on June 23, 2025, due to the TuHURA Biosciences merger agreement.

What triggered the vesting of Bartoszek's KA stock options in June 2025?

The stock options vested due to the Optionholder Treatment Agreement dated June 16, 2025, and the Agreement and Plan of Merger with TuHURA Biosciences, which was approved by stockholders at the Special Meeting on June 23, 2025. This agreement triggered full vesting of options granted under the 2022 Equity Incentive Plan.
Kineta, Inc.

NASDAQ:KA

KA Rankings

KA Latest News

KA Latest SEC Filings

KA Stock Data

7.05M
12.26M
34.89%
6%
0.23%
Biotechnology
Pharmaceutical Preparations
Link
United States
MERCER ISLAND